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Dr Thomas Yeh (New Orleans, La). I would like to thank
Dr Guleserian for sending me the report last week and the Associ-
ation for the privilege of commenting on it.
I enjoyed reading it and commend you on your efforts to learn
from this, what is clearly a challenging group of patients, judging
by the amount of timeweall continue to spend on it. A fewquestions.
Because you have attempted to characterize the course of recov-
ery with rescue banding, did you consider including a control
group of conventional Norwood procedures for comparison?
Dr Guleserian.We did look back at our conventional Norwood
mortality during the same time period. Of the 80 conventional
Norwood procedures performed, overall mortality was 13.6% in-
cluding those with presence of an extracardiac syndromes. I do not
have data in terms of the hemodynamics, the fluid balance, and so
forth, for that usual Norwood group in comparison to the PA
banded group to answer your specific question.
Dr Yeh. I realize this was a retrospective study, but what were
your specific criteria in Dallas for using this approach and have
they changed now as a result of your analysis here?
Dr Guleserian. That is a very good and key question. Any time
we encountered a patient with severe ventricular dysfunction, sig-
nificant AVVR, or IAS or RAS high-risk group, we considered
them to be high risk and suitable candidates for bilateral PA band-
ing. Additionally, if a patient presented with renal insufficiency,
renal failure, or any other end-organ dysfunction that was notThe Journal of Thoracic and Caimmediately reversed with inotropic support and/or ventilatory
changes, we would identify those patients as candidates for band-
ing. We tend to use ductal stenting less commonly if we think
that therewill be rapid hemodynamic recovery in response to band-
ing and thus be candidates for conventional Norwood pathway. For
those whom we have identified as patients who do not seem like
they are on that road to hemodynamic recovery, DS is undertaken.
Dr Yeh. After PAB was performed, you had several approaches
to the patients, including completion Norwood rather than the
comprehensive stage 2, which you commented on briefly. What
was your algorithm for a given approach (ie, DS vs prostaglandins
and, more importantly, Norwood vs CS2)? I am going to ask you
the same question Chris just asked, because some would argue
that having stabilized the patient with the hybrid stage 1.
Dr Guleserian. Why rock the boat.
Dr Yeh..Why subject the patient to the additive risk of a Nor-
wood rather than waiting for the comprehensive stage 2?
Dr Guleserian.As an institution, our bias has been toward con-
ventional Norwood. We really do not perform the CS2 procedure
given poor results with such high-risk patients. We find that if we
can rapidly turn these patients around that conventional Norwood
operation is preferred to avoid the long-term pulmonary artery
problems we have seen with long-term banded patients. For the pa-
tients who do not turn around—the ones for whom primary trans-
plantation may be the most suitable option—we would pursue DS
and discontinue prostaglandin therapy.
DrYeh.But since your original hypothesis was not met with the
equivalent mortality, perhaps that is an option to consider.
Dr Guleserian. In response to your question about whether we
have changed any of our management strategy: I think for patients,
for example, who are extremely tiny and premature, as was one of
our patients who was only 900 g, and a former 27-week-old neo-
nate, the likelihood is that they are probably not going to do
well. For these very high-risk patients who are extremely prema-
ture, have low birth weight, and have a small ascending aortas,
we will likely still try to support these patients but avoid DS
with the potential for coronary ischemia. I think that this group
is best termed the worst of the worst.
Dr Yeh. Finally, in your data, unfortunately, children weighing
less than 2.5 kg did not benefit from this approach, because the
mortality was 100%, a consistent risk factor that Drs Bacha and
Barron actually highlighted for us over the weekend. Have you
looked into the clinical behavior of that group in the perioperative
period to see whether they differ fundamentally from the patients
weighing more than 2.5 kg? Do they behave differently? Is there
something special about that group that you are noticing?
Dr Guleserian. I think the special or unique part of that partic-
ular group is that they have other significant risk factors. It is not
just the weight. They were also the ones with a gestational age
that are in the low 30s. In this specific group, 2 of the 4 neonates
were the ones with diminutive ascending aorta and I think that
our approach with DS was wrong and we should have just left
them on prostaglandins. I do not know if the outcomewould be dif-
ferent. But that is something that we have learned to avoid for the
tiniest patients with a diminutive ascending aorta.
Dr Yeh. Thanks. I enjoyed reading the report.
Dr Christopher A. Caldarone (Toronto, Ontario, Canada).
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Dthem were pretty small. Had you deployed the DS at that point or
were those patients continued with prostaglandins?
Dr Guleserian. Actually, 2 of the 3 had DSs placed. All 3
patients made it out of the operating room but they did not spend
a lot of time alive out of the operating room. There were 2 patients
who had DSs deployed at the time of banding, and I think that was
probably an error given their diminutive ascending aortas. The
third patient was a former 33-week-old, 1.8-kg patient who had
received multiple doses of surfactant after delivery and got into
a respiratory acidosis cycle that we could not get him out of.
Dr Caldarone.Well, I would just make 2 comments about that.
In our experience, bPAB is associated with an acute bump in after-
load for these hearts, and we found that they need a fair amount of
inotropic support. Also, providing that up front rather than waiting
for it to become apparent has been helpful. Also I think that is even
more apparent in the smaller neonates.
The other issue is this issue of reverse Blalock-Taussig shunts.
If these patients have events shortly after deploying of the DS, one214 The Journal of Thoracic and Cardiovascular Surgmust be worried that they had acute retrograde arch malperfusion.
If that is the case, you have a choice. You can either treat it or you
can try to prevent it. So, in Toronto, we use a preventive approach,
which might have its own set of problems, but creates an alterna-
tive source of perfusion to the aortic arch and renders the isthmus
area redundant. The alternative is to use a treatment approach.
But, as you have found, it is very hard to treat these patients after
they have developed acute compromise of retrograde arch
perfusion.
Dr Guleserian. I would agree. And I think we are quite aggres-
sive about afterload reduction. It is not unusual for us to give a dose
of phentolamine and then initiate high-dose milrinone therapy
pretty quickly. Many of these patients are coming to the operating
room on pretty high-dose ‘‘rocket fuel’’ so to speak, so they are
a very tenous group. I think all of the efforts that your group,
and efforts from the experience that we just heard about in the pre-
vious presentation, will help some of these very high-risk patients
make it when they might not otherwise.ery c January 2013
